EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey

Mahnoor Yousaf, Ahmed Farhan, Maria Zafar

Journal of Diabesity · 26.07.2025 · 1 (1)

DOI: 10.66381/jod.2025.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabesity, online erschienen am 26.07.2025. Verfasst von Mahnoor Yousaf und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a new class of antidiabetic medications that offer benefits such as weight reduction and a decreased risk of cardiovascular diseases. Nevertheless, the use of SGLT2i is associated with a range of potential side effects.The present study aimed to analyze the rate of discontinuation for empagliflozin and investigated the incidence of its side effects. Patients and Methods: This study employed a cross-sectional design using an online survey to collect data of 567 patients on pots-withdrawal symptoms of empagliflozin. Adults (≥ 18 years) who had taken empagliflozin for at least three months and had discontinued for any reasons included. Participants recruited through online platforms, including social media and online forum. The survey collected demographic information, empagliflozin use and discontinuation, reasons for discontinuation, and post-withdrawal symptoms. SPSS version 26 used for statistical analysis.

Results

Out of 567 patients, majority of patients prescribed Jardiance for diabetes 75% (n=425) and heart failure 25% (n=142). Genital infections 27% (n=109) and UTIs 22% (n=90)were the leading reasons for discontinuation followed by Dry mouth/frequent urination 17% (n=70), Lack of efficacy 14% (n=55), low blood pressure 11% (n=45), and Ketoacidosis 9% (n=35). About 67% (n=231) cases withdrawal was perceived due to adversely affect. Headache 20% (n=60) and swelling 17% (n=50) were the most common post-withdrawal symptoms.Majority of patients 68% (n=200) chose not to resume Jardiance, while 19% (n=55) considered restarting it.

Conclusion

The rate of discontinuation for empagliflozin in managing heart failure and diabetes is relatively low, indicating its effectiveness in improving glycemic control, cardiovascular outcomes, and weight loss. Empagliflozin has been shown to reduce the mortality and risk of hospitalization heart failurepatients with improve weight loss, glycemic control, and reduced ejection fraction in type 2 diabetes patients.

Zitieren

APA

Yousaf, M., Farhan, A., & Zafar, M. (2025). Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey. Journal of Diabesity, 1(1). https://doi.org/10.66381/jod.2025.001

Vancouver

Yousaf M, Farhan A, Zafar M. Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey. Journal of Diabesity. 2025;1(1). doi:10.66381/jod.2025.001

BibTeX
@article{Yousaf2025,
  author = {Yousaf, Mahnoor and Farhan, Ahmed and Zafar, Maria},
  title = {Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey},
  journal = {Journal of Diabesity},
  year = {2025},
  volume = {1},
  number = {1},
  doi = {10.66381/jod.2025.001}
}
Kostenlos starten →